Rigel – $46 Million Shelf-Takedown

San Francisco – February 17, 2017 – Cooley advised Rigel Pharmaceuticals on its $46 million shelf-takedown offering of 23,000,000 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares.

Jefferies, Piper Jaffray & Co. and BMO Capital Markets acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

Rigel, which trades on the NASDAQ Global Select Market as "RIGL," is a clinical-stage biotech company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Its pioneering research focuses on signaling pathways that are critical to disease mechanisms.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
David Peinsipp Partner, San Francisco
Carlton Fleming Partner, Palo Alto
David Ambler Associate, Palo Alto
Allison Pang Associate, Palo Alto
Diane James Senior Paralegal, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Carol Laherty Partner, Seattle
Susan Cooper Philpot Partner, San Francisco
Josh Kaufman Partner, New York
Francis Wheeler Partner, Colorado
Related Practices & Industries

Life Sciences Capital Markets Public Companies